Jazz Pharmaceuticals plc (JAZZ) Guidance & Earnings Results

On 2026-08-03 Jazz Pharmaceuticals plc raised guidance: "FY26 revenue guidance raised to $4.60-$4.75 billion from prior range (not explicitly stated but implied…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

JAZZJazz Pharmaceuticals plcFollow JAZZ — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 13.9B
P/E TTM: 14.6
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
3 Aug 26	Raised	FY26 revenue guidance raised to $4.60-$4.75 billion from prior range (not explicitly stated but implied increase) · full year
5 May 26	Reaffirmed	2026 revenue and expense guidance reaffirmed · full year
24 Feb 26	Raised	2026 revenue guidance $4.25B-$4.5B · full year
12 Jan 26	Reaffirmed	Reaffirmed 2025 total revenue guidance · full year
5 Nov 25	Raised	Revenue guidance narrowed to $4.175-$4.275B from $4.150-$4.300B · full year
5 Aug 25	Raised	FY25 total revenue $4.15-4.30B (prior $4.10-4.30B implied); raising lower end of net income and EPS ranges · full year

Jazz Pharmaceuticals plc — questions

What guidance did Jazz Pharmaceuticals plc give?: On 2026-08-03: "FY26 revenue guidance raised to $4.60-$4.75 billion from prior range (not explicitly stated but implied increase)"
When does Jazz Pharmaceuticals plc report earnings?: Jazz Pharmaceuticals plc's next earnings report is expected on 2026-11-02.

Every figure on this page comes from Jazz Pharmaceuticals plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.